METHODS OF TREATMENT FOR COAGULOPATHY

Claims

Methods of treating coagulopathy using a bispecific antibody comprising (i) a first antigen-binding site capable of binding to factor VII(a), and (ii) a second antigen-binding site capable of binding to TREM-like transcript 1 (TLT-1).

1. A method for treating coagulopathy in a subject, wherein the method comprises a step of administering to the subject a pharmaceutical composition comprising a bispecific antibody comprising (i) a first antigen-binding site capable of binding to Factor VII(a), and (ii) a second antigen-binding site capable of binding to TREM-like Transcript 1 (TLT-1), in a dose of approximately 0.3 mg / kg, approximately 0.6 mg / kg or approximately 0.9 mg / kg of the bispecific antibody at regular intervals of at least approximately one week, approximately two weeks, approximately three weeks or approximately one month.